Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Status:
Not yet recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
Multicenter, open-label Phase 1b/2 study of ripretinib in combination with binimetinib in
patients with gastrointestinal stromal tumor (GIST). There will be 2 distinct parts in this
study: Dose Escalation (Phase 1) and Expansion (Phase 2).